Abstract:Drug resistance remains to be a serious problem with type I human immunodeficiency virus (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs). A series of novel boronic acid-containing diarylpyrimidine (DAPY) derivatives were designed via bioisosterism and scaffold-hopping strategies, taking advantage of the ability of a boronic acid group to form multiple hydrogen bonds. The target compounds were synthesized and evaluated for their anti-HIV activities and cytotoxicity in MT-4 cells. Compound 10j yielded the most potent activity and turned out to be a single-digit nanomolar inhibitor towards the HIV-1 IIIB [wild-type (WT) strain], L100I and K103N strains, with 50% effective concentration (EC50) values of 7.19-9.85 nmol/L. Moreover, 10j inhibited the double-mutant strain RES056 with an EC50 value of 77.9 nmol/L, which was 3.3-more potent than that of EFV (EC50 = 260 nmol/L) and comparable to that of ETR (EC50 = 32.2 nmol/L). 10j acted like classical NNRTIs with high affinity for WT HIV-1 reverse transcriptase (RT) with 50% inhibition concentration (IC50) value of 0.1837 mu mol/L. Furthermore, molecular dynamics simulation indicated that 10j was proposed as a promising molecule for fighting against HIV-1 infection through inhibiting RT activity. Overall, the results demonstrated that 10j could serve as a lead molecule for further modification to address virus-drug resistance. (C) 2021 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

Identification of Boronate-Containing Diarylpyrimidine Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Identification of Dihydrofuro[3,4- D]pyrimidine Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Hybrid Diarylbenzopyrimidine Non-Nucleoside Reverse Transcriptase Inhibitors As Promising New Leads for Improved Anti-Hiv-1 Chemotherapy

Design, Synthesis, and Evaluation of Diarylpyridines and Diarylanilines As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Boronic Acid-Containing Diarylpyrimidine Derivatives As Novel HIV-1 NNRTIs: Design, Synthesis and Biological Evaluation

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation

Identification of Novel Diarylpyrimidines As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region

Discovery of Piperidin-4-yl-aminopyrimidine Derivatives As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Discovery of Diarylpyridine Derivatives As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Synthesis and Biological Evaluation of Dihydroquinazoline-2-amines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors of Wild-Type and Mutant HIV-1 Strains.

Discovery of Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Structure-Activity Relationship of Solvent-Exposed Regions I.

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses

Targeting the Entrance Channel of NNIBP: Discovery of Diarylnicotinamide 1,4-Disubstituted 1,2,3-Triazoles As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and E138K Mutant Virus

Exploring the Hydrophobic Channel of NNIBP Leads to the Discovery of Novel Piperidine-Substituted Thiophene[3,2-D]pyrimidine Derivatives As Potent HIV-1 NNRTIs

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives As Potent HIV-1 NNRTIs.

Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives As HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.

Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.

Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.